A review of relative dose intensity and survival in patients with metastatic solid tumors

Highlights • Few studies analyzed the association of RDI with outcomes in metastatic disease. • The effect of RDI on survival in metastatic or recurrent cancer remains unclear. • Researchers are using various methods to calculate RDI. • The methods for calculating RDI are often not clearly discussed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2015-03, Vol.93 (3), p.203-210
Hauptverfasser:	Havrilesky, Laura J, Reiner, Maureen, Morrow, Phuong Khanh, Watson, Holly, Crawford, Jeffrey
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Hematology, Oncology and Palliative Medicine Humans Lung cancer Metastatic disease Neoplasm Metastasis Neoplasms - drug therapy Neoplasms - mortality Neoplasms - pathology Outcomes Ovarian cancer Prognosis Relative dose intensity Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Few studies analyzed the association of RDI with outcomes in metastatic disease. • The effect of RDI on survival in metastatic or recurrent cancer remains unclear. • Researchers are using various methods to calculate RDI. • The methods for calculating RDI are often not clearly discussed in the publications.
ISSN:	1040-8428 1879-0461
DOI:	10.1016/j.critrevonc.2014.10.006